Medtronic Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Los beneficios de Medtronic han disminuido a una tasa media anual de -2.6%, mientras que en la industria Medical Equipment los beneficios crecieron en un 4.3% anualmente. Los ingresos han ido creciendo a una tasa media de 1.4% al año. La rentabilidad financiera de Medtronic es de 8.1%, y sus márgenes netos son de 13%.

Información clave

-2.6%

Tasa de crecimiento de los beneficios

-2.4%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	4.3%
Tasa de crecimiento de los ingresos	1.4%
Rentabilidad financiera	8.1%
Margen neto	13.0%
Próxima actualización de resultados	23 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Medtronic. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

XTRA:2M6 Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
26 Jan 24	32,320	4,201	12,000	2,701
27 Oct 23	31,958	4,102	11,884	2,693
28 Jul 23	31,558	3,620	11,860	2,672
28 Apr 23	31,227	3,758	11,801	2,696
27 Jan 23	30,771	4,064	11,825	2,707
28 Oct 22	30,806	4,321	11,749	2,688
29 Jul 22	31,070	5,205	11,698	2,688
29 Apr 22	31,686	5,039	11,720	2,746
28 Jan 22	31,785	4,914	10,015	2,726
29 Oct 21	31,798	4,704	9,957	2,659
30 Jul 21	31,597	3,882	9,997	2,622
30 Apr 21	30,117	3,606	9,956	2,493
29 Jan 21	27,926	2,892	9,543	2,429
30 Oct 20	27,868	3,537	9,661	2,401
31 Jul 20	27,927	4,412	9,644	2,365
24 Apr 20	28,913	4,789	9,882	2,331
24 Jan 20	31,062	5,408	11,857	2,357
25 Oct 19	30,891	4,762	11,889	2,345
26 Jul 19	30,666	4,420	10,105	2,332
26 Apr 19	30,557	4,631	10,273	2,330
25 Jan 19	30,555	4,826	11,912	2,328
26 Oct 18	30,378	2,168	11,844	2,326
27 Jul 18	29,947	3,163	9,963	2,292
27 Apr 18	29,953	3,104	10,077	2,256
26 Jan 18	29,725	2,859	11,993	2,217
27 Oct 17	29,639	5,069	11,878	2,188
28 Jul 17	29,934	4,115	9,813	2,186
28 Apr 17	29,710	4,028	9,715	2,193
27 Jan 17	29,361	3,968	9,592	2,215
28 Oct 16	29,012	4,242	9,521	2,231
29 Jul 16	28,725	3,647	9,448	2,222
29 Apr 16	28,833	3,538	9,469	2,224
29 Jan 16	28,435	2,434	9,513	2,177
30 Oct 15	25,819	2,316	8,683	2,004
31 Jul 15	23,127	2,624	7,847	1,833
24 Apr 15	20,261	2,675	6,904	1,640
23 Jan 15	17,410	3,124	6,039	1,497
24 Oct 14	17,255	2,909	6,006	1,484
25 Jul 14	17,083	2,983	5,937	1,482
25 Apr 14	16,893	3,065	5,847	1,477
24 Jan 14	16,879	3,586	5,783	1,501
25 Oct 13	16,743	3,812	5,730	1,517
26 Jul 13	16,644	3,556	5,709	1,532

Ingresos de calidad: 2M6 tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(13%) de 2M6 son inferiores a los del año pasado (13.2%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de 2M6 han disminuido en un 2.6% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de 2M6 en el último año (3.3%) supera su media de 5 años (-2.6% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de 2M6 en el último año (3.3%) superó al de la industria Medical Equipment -6.1%.

Medtronic Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Información clave

Actualizaciones de resultados anteriores recientes

Third quarter 2024 earnings released: EPS: US$0.99 (vs US$0.92 in 3Q 2023)

Medtronic plc to Report Q3, 2025 Results on Feb 18, 2025

Second quarter 2024 earnings released: EPS: US$0.68 (vs US$0.32 in 2Q 2023)

First quarter 2024 earnings released: EPS: US$0.59 (vs US$0.70 in 1Q 2023)

Full year 2023 earnings released: EPS: US$2.83 (vs US$3.75 in FY 2022)

Full year 2023 earnings released: EPS: US$2.83 (vs US$3.75 in FY 2022)

Recent updates

Medtronic plc Receives FDA Approval for Inceptiv Closed-Loop Spinal Cord Stimulator

Medtronic plc Announces New Advancements in Artificial Intelligence for Endoscopic Care by Unveiling ColonPRO

Medtronic plc Announces SMART Trial One-Year Data Demonstrates Medtronic Evolut™ Tavr Platform as Optimal Treatment for Severe Aortic Stenosis in Patients with Small Annulus, Which Is Primarily Women

Now 20% undervalued

Upcoming dividend of US$0.69 per share

Third quarter dividend of US$0.69 announced

Medtronic plc Presents New Clinical and Real-World Data on the MiniMed™ 780G System from Around the World

Medtronic plc Approves Cash Dividend for the Fourth Quarter of Fiscal Year 2024, Payable on April 12, 2024

Now 20% undervalued

Third quarter 2024 earnings released: EPS: US$0.99 (vs US$0.92 in 3Q 2023)

Now 20% undervalued

Medtronic plc to Report Q3, 2025 Results on Feb 18, 2025

Medtronic plc Announces FDA Approval of Its Percept™? RC Deep Brain Stimulation System

Medtronic Diabetes Announces World's First Approval for MiniMed™ 780G System with Simplera Sync™ Disposable, all-in-one sensor

Medtronic plc Announces FDA Approves the PulseSelect Pulsed Field Ablation System for the Treatment of Both Paroxysmal and Persistent Atrial Fibrillation

Upcoming dividend of US$0.69 per share at 3.5% yield

Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2024, Payable on January 12, 2024

Second quarter 2024 earnings released: EPS: US$0.68 (vs US$0.32 in 2Q 2023)

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2024

Medtronic plc Announces Four-Year Results from the Evolut Low Risk Trial

Now 20% undervalued after recent price drop

Orchestra BioMed Holdings, Inc Grants FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Upcoming dividend of US$0.69 per share at 3.4% yield

Medtronic Issues Statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System

Medtronic plc Raises Earnings Guidance for 2024

New minor risk - Profit margin trend

First quarter 2024 earnings released: EPS: US$0.59 (vs US$0.70 in 1Q 2023)

Medtronic plc Approves Cash Dividend for the Second Quarter of Fiscal Year 2024, Payable on October 13, 2023

Full year 2023 earnings released: EPS: US$2.83 (vs US$3.75 in FY 2022)

Medtronic plc Appoints Greg Lewis as New Director

Medtronic plc Presents New Data on MiniMed 780G System on Fixed Meal Dosing and Real-World Time in Range Across Wide Range of Users

Upcoming dividend of US$0.69 per share at 3.1% yield

Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer

Full year 2023 earnings released: EPS: US$2.83 (vs US$3.75 in FY 2022)

Medtronic plc Approves Cash Dividend for the First Quarter of Fiscal Year 2024, Payable on July 14, 2023

Medtronic plc Announces Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Upcoming dividend of US$0.68 per share at 3.5% yield

Third quarter 2023 earnings released: EPS: US$0.92 (vs US$1.10 in 3Q 2022)

Medtronic plc to Report Q3, 2024 Results on Feb 20, 2024

Medtronic Linq Insertable Cardiac Monitor Detects 10 Times More Atrial Fibrillation in Ischemic Stroke Patients At Three Years Compared to Standard of Care

Siemens Healthineers, GE Healthcare Studying Potential Deals with Medtronic's Spun Off Units

Medtronic Announces First Patient Enrolled in U.S. Clinical Trial for Hugo™ Robotic-Assisted Surgery System

Upcoming dividend of US$0.68 per share

Medtronic plc Approves Cash Dividend for the Third Quarter of Fiscal Year 2023, Payable on January 13, 2023

Medtronic Completes Enrollment in Pivotal Trial Evaluating First-Of-Its-Kind Pulsed Field Ablation Catheter for Patients with Atrial Fibrillation

Second quarter 2023 earnings released: EPS: US$0.32 (vs US$0.97 in 2Q 2022)

Medtronic plc Provides Revenue Results for the Second Half of 2023

Medtronic's SPYRAL HTN-ON MED Study Demonstrates Meaningful Clinical Benefits Consistent with Other SPYRAL HTN Renal Denervation Trials

Medtronic plc Launches of Medtronic Neurovascular Co-Lab Platform to Accelerate Innovation in Stroke Treatment

dorsaVi Partners with Medtronic to Develop New Technology

Medtronic plc Introduces New Program Called My Insights Exclusively Made for Individuals Using MiniMed™ 770G System

Medtronic plc to Receive FDA Approval for Pacing the Heart's Natural Conduction System

Medtronic plc Receives FDA Clearance for Expanded Indication of LINQ II™ Insertable Cardiac Monitor for Use in Pediatric Patients Ages 2 and Older

Medtronic plc Announces SYMPLICITY HTN-3 Trial Data Show Sustained Long-Term Blood Pressure Reductions with Medtronic Renal Denervation Procedure

Now 20% undervalued

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta